deferoxamine has been researched along with Chronic Disease in 31 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| " A total of 27 patients with chronic hepatitis B viral infection, who had elevated serum ferritin levels, were randomized to receive either IFN 5 MU, three times weekly by subcutaneous injection alone (n = 14) or in combination with cycles of deferoxamine at a dose od 80 mg kg-1 per cycle (n = 13) administered over 3 consecutive days, to reduce their iron and maintain a serum ferritin level less than 250 ng ml-1." | 9.08 | The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B. ( Bayraktar, Y; De Maria, N; Kayhan, B; Koseoglu, T; Somner, C; Temizer, A; Uzunalimoglu, B; Van Thiel, DH, 1996) |
| "All of 34 patients with untreated hemochromatosis had distinctly elevated values for deferoxamine-chelatable iron." | 5.26 | Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload. ( Baggenstoss, AH; Baldus, WP; Dickson, ER; Fairbanks, VF, 1978) |
| " A total of 27 patients with chronic hepatitis B viral infection, who had elevated serum ferritin levels, were randomized to receive either IFN 5 MU, three times weekly by subcutaneous injection alone (n = 14) or in combination with cycles of deferoxamine at a dose od 80 mg kg-1 per cycle (n = 13) administered over 3 consecutive days, to reduce their iron and maintain a serum ferritin level less than 250 ng ml-1." | 5.08 | The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B. ( Bayraktar, Y; De Maria, N; Kayhan, B; Koseoglu, T; Somner, C; Temizer, A; Uzunalimoglu, B; Van Thiel, DH, 1996) |
| " The introduction of effective chelation therapy protocols using primarily deferiprone (L1) in combination with deferoxamine (DFO) resulted in the reduction of iron overload induced cardiac failures, which is the main cause of death in thalassemia major." | 3.75 | Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications. ( Kolnagou, A; Kontoghiorghes, GJ, 2009) |
| " Further, there is lack of agreement about the benefits of deferoxamine (Dfx) in the treatment of anemia and oxidative stress during inflammation and chronic diseases." | 3.69 | Iron metabolism and oxidative stress during acute and chronic phases of experimental inflammation: effect of iron-dextran and deferoxamine. ( Mitjavila, MT; Muntané, J; Puig-Parellada, P, 1995) |
| "Chronic progressive Multiple Sclerosis is refractory to many conventional treatments." | 2.68 | Desferrioxamine in chronic progressive multiple sclerosis: a pilot study. ( LeVine, SM; Lynch, SG; Peters, K, 1996) |
| "Post-hemorrhagic chronic hydrocephalus (PHCH) is a common complication after intraventricular hemorrhage (IVH)." | 1.42 | Deferoxamine alleviates chronic hydrocephalus after intraventricular hemorrhage through iron chelation and Wnt1/Wnt3a inhibition. ( Feng, H; Gong, G; Hu, R; Hu, S; Li, F; Meng, H; Yuan, Y, 2015) |
| "Liver fibrosis was additionally suppressed in the bile-duct ligation model by ID." | 1.35 | Attenuation of acute and chronic liver injury in rats by iron-deficient diet. ( Ikeda, K; Kawada, N; Nakajima, Y; Nakatani, K; Ogawa, T; Otogawa, K; Shiga, R, 2008) |
| " Since dose-response curves were highly variable the treatment schedule should be tailored to the individual needs of each patient." | 1.26 | Iron chelation in transfusion-dependent thalassemia with chronic hepatitis. ( Cao, A; Cornacchia, G; Cossu, P; De Virgiliis, S; Frau, F; Lobrano, R; Loi, A; Loi, E; Nucaro, A; Sanna, G; Toccafondi, C, 1982) |
| "All of 34 patients with untreated hemochromatosis had distinctly elevated values for deferoxamine-chelatable iron." | 1.26 | Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload. ( Baggenstoss, AH; Baldus, WP; Dickson, ER; Fairbanks, VF, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (48.39) | 18.7374 |
| 1990's | 9 (29.03) | 18.2507 |
| 2000's | 5 (16.13) | 29.6817 |
| 2010's | 2 (6.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tchanque-Fossuo, CN | 1 |
| Dahle, SE | 1 |
| Buchman, SR | 1 |
| Isseroff, RR | 1 |
| Meng, H | 1 |
| Li, F | 1 |
| Hu, R | 1 |
| Yuan, Y | 1 |
| Gong, G | 1 |
| Hu, S | 1 |
| Feng, H | 1 |
| McLeod, C | 1 |
| Fleeman, N | 1 |
| Kirkham, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Chu, P | 1 |
| Dickson, R | 1 |
| Dundar, Y | 1 |
| Greenhalgh, J | 1 |
| Modell, B | 1 |
| Olujohungbe, A | 1 |
| Telfer, P | 1 |
| Walley, T | 1 |
| Kolnagou, A | 1 |
| Kontoghiorghes, GJ | 1 |
| Otogawa, K | 1 |
| Ogawa, T | 1 |
| Shiga, R | 1 |
| Nakatani, K | 1 |
| Ikeda, K | 1 |
| Nakajima, Y | 1 |
| Kawada, N | 1 |
| De Virgiliis, S | 1 |
| Cossu, P | 1 |
| Sanna, G | 1 |
| Frau, F | 1 |
| Loi, E | 1 |
| Lobrano, R | 1 |
| Nucaro, A | 1 |
| Toccafondi, C | 1 |
| Cornacchia, G | 1 |
| Loi, A | 1 |
| Cao, A | 1 |
| Blake, DR | 1 |
| Hall, ND | 1 |
| Bacon, PA | 1 |
| Dieppe, PA | 1 |
| Halliwell, B | 1 |
| Gutteridge, JM | 1 |
| Muntané, J | 1 |
| Puig-Parellada, P | 1 |
| Mitjavila, MT | 1 |
| Benso, L | 1 |
| Gambotto, S | 1 |
| Pastorin, L | 1 |
| Signorile, F | 1 |
| Tanner, JM | 1 |
| Leonardi, S | 1 |
| Musumeci, S | 1 |
| Panico, F | 1 |
| Salvati, A | 1 |
| Scoppa, F | 1 |
| Testa, GF | 1 |
| Capobianco, A | 1 |
| Pacia, S | 1 |
| Lauriello, F | 1 |
| Aquino, A | 1 |
| Tedesco, V | 1 |
| Taccone, W | 1 |
| Salvarani, C | 1 |
| Baricchi, R | 1 |
| Lasagni, D | 1 |
| Boiardi, L | 1 |
| Piccinini, R | 1 |
| Brunati, C | 1 |
| Macchioni, P | 1 |
| Portioli, I | 1 |
| Bayraktar, Y | 1 |
| Koseoglu, T | 1 |
| Somner, C | 1 |
| Kayhan, B | 1 |
| Temizer, A | 1 |
| Uzunalimoglu, B | 1 |
| De Maria, N | 1 |
| Van Thiel, DH | 1 |
| Lynch, SG | 1 |
| Peters, K | 1 |
| LeVine, SM | 1 |
| Gupta, R | 1 |
| Gupta, S | 1 |
| Joshi, K | 1 |
| Ganguly, NK | 1 |
| Karasu, C | 1 |
| Bergeron, RJ | 1 |
| Wiegand, J | 1 |
| Brittenham, GM | 1 |
| M'Seffar, A | 1 |
| Fornasier, VL | 1 |
| Fox, IH | 1 |
| Guilmette, RA | 1 |
| Cerny, EA | 1 |
| Rahman, YE | 1 |
| Baldus, WP | 1 |
| Fairbanks, VF | 1 |
| Dickson, ER | 1 |
| Baggenstoss, AH | 1 |
| Capaccioli, L | 1 |
| D'Ambrosio, A | 1 |
| Paciotti, F | 1 |
| Acquaviva, A | 1 |
| Morgese, G | 1 |
| Rocchi, E | 1 |
| Cassanelli, M | 1 |
| Borghi, A | 1 |
| Paolillo, F | 1 |
| Pradelli, M | 1 |
| Pellizzardi, S | 1 |
| Vezzosi, A | 1 |
| Gallo, E | 1 |
| Baccarani Contri, M | 1 |
| Ventura, E | 1 |
| Ureña, P | 1 |
| Basile, C | 1 |
| Grateau, G | 1 |
| Lacour, B | 1 |
| Vassault, A | 1 |
| Bourdeau, A | 1 |
| Bourdon, R | 1 |
| Dubost, C | 1 |
| Zingraff, J | 1 |
| Drüeke, T | 1 |
| Giordano, R | 1 |
| Ioppolo, A | 1 |
| Ciaralli, L | 1 |
| Rubbiani, M | 1 |
| Vernillo, I | 1 |
| Costantini, S | 1 |
| Passlick, J | 1 |
| Wilhelm, M | 1 |
| Busch, T | 1 |
| Grabensee, B | 1 |
| Ohnesorge, FK | 1 |
| De Sanctis, V | 1 |
| D'Ascola, G | 1 |
| Wonke, B | 1 |
| Williams, JW | 1 |
| Vera, SR | 1 |
| Peters, TG | 1 |
| Luther, RW | 1 |
| Bhattacharya, S | 1 |
| Spears, H | 1 |
| Graham, A | 1 |
| Pitcock, JA | 1 |
| Crawford, AJ | 1 |
| Palmieri, GM | 1 |
| Schimmelpfennig, W | 1 |
| Wagner, K | 1 |
| Schneider, G | 1 |
| Zimmermann, HB | 1 |
| Fainshtein, FE | 1 |
| Trubina, NS | 1 |
| Sobaleva, IuG | 1 |
| Rozanova, NS | 1 |
| Voronina, AN | 1 |
| Lange, J | 1 |
2 reviews available for deferoxamine and Chronic Disease
| Article | Year |
|---|---|
Deferoxamine: potential novel topical therapeutic for chronic wounds.
Topics: Administration, Cutaneous; Chronic Disease; Deferoxamine; Humans; Iron; Siderophores; Skin Ulcer; Wo | 2017 |
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferipro | 2009 |
3 trials available for deferoxamine and Chronic Disease
| Article | Year |
|---|---|
Growth velocity monitoring of the efficacy of different therapeutic protocols in a group of thalassaemic children.
Topics: Chelation Therapy; Child; Child, Preschool; Chronic Disease; Deferoxamine; Female; Ferritins; Follow | 1995 |
The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Chronic Disease; Deferoxamine; DNA, Viral; Drug Syner | 1996 |
Desferrioxamine in chronic progressive multiple sclerosis: a pilot study.
Topics: Adult; Antidotes; Chronic Disease; Deferoxamine; Female; Hearing Tests; Humans; Male; Middle Aged; M | 1996 |
26 other studies available for deferoxamine and Chronic Disease
| Article | Year |
|---|---|
Deferoxamine alleviates chronic hydrocephalus after intraventricular hemorrhage through iron chelation and Wnt1/Wnt3a inhibition.
Topics: Animals; Blotting, Western; Brain; Cerebral Hemorrhage; Chronic Disease; Deferoxamine; Disease Model | 2015 |
Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
Topics: Chelation Therapy; Chronic Disease; Cyprus; Deferiprone; Deferoxamine; Female; Ferritins; Genetic Te | 2009 |
Attenuation of acute and chronic liver injury in rats by iron-deficient diet.
Topics: Acute Disease; Animals; Apoptosis; Chemokine CCL2; Chronic Disease; Deferoxamine; Hepatocytes; Inter | 2008 |
Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
Topics: Adolescent; Alanine Transaminase; Child; Child, Preschool; Chronic Disease; Deferoxamine; Female; Fe | 1982 |
Effect of a specific iron chelating agent on animal models of inflammation.
Topics: Acute Disease; Animals; Brain; Catalysis; Chronic Disease; Deferoxamine; Disease Models, Animal; Fem | 1983 |
Iron metabolism and oxidative stress during acute and chronic phases of experimental inflammation: effect of iron-dextran and deferoxamine.
Topics: Acute Disease; Anemia, Iron-Deficiency; Animals; Carrageenan; Chronic Disease; Deferoxamine; Disease | 1995 |
Could chelation therapy with deferoxamine enhance the percentage of responders to interferon therapy in chronic hepatitis C?
Topics: Chelation Therapy; Chronic Disease; Combined Modality Therapy; Deferoxamine; Drug Synergism; Ferriti | 1993 |
[Interaction between active metabolites of vitamin D3 and blood aluminum in chronic uremic patients on dialysis].
Topics: Adolescent; Adult; Aged; Aluminum; Aluminum Hydroxide; Calcitriol; Chronic Disease; Deferoxamine; Dr | 1993 |
Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis.
Topics: Anemia; Arthritis, Rheumatoid; Chronic Disease; Deferoxamine; Dose-Response Relationship, Drug; Enzy | 1996 |
Role of iron and iron chelation therapy in oxygen free radical mediated tissue injury in an ascending mouse model of chronic pyelonephritis.
Topics: Animals; Chelation Therapy; Chronic Disease; Citric Acid; Deferoxamine; Disease Models, Animal; Drug | 1997 |
Time course of changes in endothelium-dependent and -independent relaxation of chronically diabetic aorta: role of reactive oxygen species.
Topics: Acetylcholine; Amitrole; Animals; Aorta, Thoracic; Blood Glucose; Body Weight; Catalase; Chronic Dis | 2000 |
HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
Topics: Acute Disease; Animals; Blood Pressure; Cebus; Chronic Disease; Deferoxamine; Disease Models, Animal | 2002 |
Research findings of potential value to the practitioner.
Topics: Bronchitis; Chronic Disease; Deferoxamine; Diagnosis, Differential; Hematologic Diseases; Injections | 1977 |
Arthropathy as the major clinical indicator of occult iron storage disease.
Topics: Adult; Arthritis; Cartilage, Articular; Chronic Disease; Deferoxamine; Female; Hemochromatosis; Hemo | 1977 |
Pharmacokinetics of the iron chelator desperrioxamine as affected by liposome encapsulation: potential in treatment of chronic hemosiderosis.
Topics: Animals; Capsules; Chronic Disease; Deferoxamine; Female; Hemosiderosis; Injections, Intravenous; Ir | 1978 |
Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload.
Topics: Adult; Anemia; Chronic Disease; Deferoxamine; Hemochromatosis; Humans; Iron; Iron Chelating Agents; | 1978 |
[Idiopathic pulmonary hemosiderosis].
Topics: Child, Preschool; Chronic Disease; Cortisone; Deferoxamine; Female; Hemosiderosis; Humans; Immunosup | 1978 |
Liver iron overload and desferrioxamine treatment of porphyria cutanea tarda.
Topics: Bloodletting; Chromatography, High Pressure Liquid; Chronic Disease; Deferoxamine; Ferritins; Humans | 1991 |
Short-term effects of parathyroidectomy on plasma biochemistry in chronic uremia.
Topics: Alkaline Phosphatase; Aluminum; Bone and Bones; Calcifediol; Calcium; Chronic Disease; Cohort Studie | 1989 |
Aluminum removal after chronic intoxication in rats.
Topics: Aluminum; Animals; Bone and Bones; Chronic Disease; Deferoxamine; Male; Rats; Rats, Inbred Strains; | 1989 |
[Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine].
Topics: Aluminum; Chronic Disease; Deferoxamine; Female; Humans; Middle Aged; Peritoneal Dialysis, Continuou | 1989 |
The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients.
Topics: Adolescent; Adult; Blood Glucose; Child; Chronic Disease; Deferoxamine; Diabetes Mellitus; Female; F | 1986 |
Biliary excretion of aluminum in aluminum osteodystrophy with liver disease.
Topics: Adult; Aluminum; Aluminum Hydroxide; Bile; Bone and Bones; Bone Diseases, Metabolic; Chronic Disease | 1986 |
[Indications for treatment of chronic hepatitis and liver cirrhosis and their complications. 1. Treatment of chronic hepatitis and liver cirrhosis].
Topics: Azathioprine; Cholecalciferol; Chronic Disease; Deferoxamine; Glucocorticoids; Hepatitis; Humans; Li | 1974 |
[Use of desferal and some data on hemosiderosis in hypo- and aplastic anemias].
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Chronic Disease; Deferoxamine; Female; Hemochrom | 1968 |
[Chemica damage to the eye in industrial medicine].
Topics: Argyria; Burns, Chemical; Caustics; Chelating Agents; Chronic Disease; Copper; Deferoxamine; Dimerca | 1969 |